Análisis comparativo de la proteína C reactiva frente a la procalcitonina en la predicción de infecciones respiratorias bacterianas en adultos
DOI:
https://doi.org/10.63969/5axbjt60Palabras clave:
proteína C reactiva, procalcitonina, infección respiratoria bacteriana, biomarcadores, diagnósticoResumen
Este artículo de revisión compara el rendimiento diagnóstico y pronóstico de la proteína C reactiva (CRP) y la procalcitonina (PCT) en la detección de infecciones bacterianas respiratorias en adultos. Se analizó evidencia publicada entre 2004 y 2025, incluyendo estudios observacionales, ensayos clínicos y metaanálisis. Los hallazgos muestran que la CRP presenta mayor sensibilidad, mientras que la PCT ofrece mejor especificidad y una respuesta cinética más rápida al inicio y resolución de la infección. La combinación de ambos biomarcadores surge como una estrategia equilibrada para mejorar la precisión diagnóstica, optimizar el uso de antibióticos y apoyar los programas de vigilancia antimicrobiana. Se discuten las implicaciones clínicas, las limitaciones metodológicas y las áreas de investigación futura, destacando la necesidad de protocolos diagnósticos estandarizados y estudios de costo-efectividad.
Referencias
Azzini, A. M., et al. (2020). Procalcitonin and C-reactive protein in septic patients: Clinical and prognostic value. Annals of Translational Medicine, 8(10), 640. https://doi.org/10.21037/atm.2020.03.112
Bafadhel, M., et al. (2011). Procalcitonin and C-reactive protein in hospitalized adults: Distinguishing pneumonia from asthma exacerbations. Chest, 139(6), 1410–1418. https://doi.org/10.1378/chest.10-1747
Bhat, A., et al. (2025). Procalcitonin is a superior early biomarker compared to C-reactive protein for detecting invasive bacterial infections in pediatric emergency departments. International Journal of Emergency Medicine.https://doi.org/10.1186/s12245-025-00888-2
Boeck, L., et al. (2011). Midregional pro-atrial natriuretic peptide and procalcitonin in guiding therapy for lower respiratory tract infections. European Respiratory Journal, 37(3), 595–603. https://doi.org/10.1183/09031936.00051309
Doganci, M., et al. (2024). The utility of C-reactive protein, procalcitonin, and leukocyte count changes in prognosis of pneumonia-related septic shock. Preprints. https://doi.org/10.20944/preprints202408.1007.v1
Duan, S., et al. (2021). Combining C-reactive protein or procalcitonin with clinical features to distinguish bacterial from viral lower respiratory tract infections in adults. BMC Pulmonary Medicine, 21, 308. https://doi.org/10.1186/s12890-021-01672-7
Gutierrez-Gutierrez, B., et al. (2019). Kinetics of procalcitonin and C-reactive protein for monitoring sepsis and respiratory infections. Journal of Critical Care, 50, 239–245. https://doi.org/10.1016/j.jcrc.2018.12.006
Hoeboer, S. H., & Groeneveld, A. B. (2013). Changes in circulating procalcitonin versus C-reactive protein in predicting evolution of infectious disease in febrile, critically ill patients. PLoS ONE, 8(6), e65564. https://doi.org/10.1371/journal.pone.0065564
Holm, A., et al. (2007). Procalcitonin versus C-reactive protein for predicting lower respiratory tract bacterial infection including pneumonia. British Journal of General Practice, 57(540), 555–560.
Katz, S. E., et al. (2021). Comparisons of serial PCT and CRP in hospitalized children with serious bacterial infections: Kinetics and clinical implications. Infectious Diseases and Therapy. https://doi.org/10.1007/s40121-020-00358-7
Lubell, Y., et al. (2015). Discriminating viral and bacterial infections in malaria-endemic Southeast Asia: Performance of CRP and PCT. BMC Infectious Diseases, 15, 511. https://doi.org/10.1186/s12879-015-1272-6
Meili, M., et al. (2016). Infection biomarkers in primary-care patients with acute respiratory infections: Low correlation between C-reactive protein and procalcitonin. BMC Pulmonary Medicine, 16, 128. https://doi.org/10.1186/s12890-016-0206-4
Norman-Bruce, H., et al. (2024). Diagnostic test accuracy of procalcitonin and C-reactive protein in predicting invasive or serious bacterial infections in febrile infants. The Lancet Child & Adolescent Health. https://doi.org/10.1016/S2352-4642(24)00021-X
Schuetz, P., et al. (2009). Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections. Cochrane Database of Systematic Reviews, 2009(4), CD007498. https://doi.org/10.1002/14651858.CD007498.pub2
Shi, J., et al. (2024). Procalcitonin and C-reactive protein as diagnostic biomarkers in COVID-19 and non-COVID-19 sepsis patients: A comparative study. BMC Infectious Diseases, 24, 45. https://doi.org/10.1186/s12879-023-08962-x
Simon, L., Gauvin, F., Amre, D. K., Saint-Louis, P., & Lacroix, J. (2004). Serum procalcitonin and C-reactive protein levels as markers of bacterial infection: A systematic review and meta-analysis. Clinical Infectious Diseases, 39(2), 206–217. https://doi.org/10.1086/421997
Tissières, P., et al. (2025). Use of procalcitonin in therapeutic decisions in the pediatric intensive care unit: Guidance for critically ill children. Annals of Intensive Care. https://doi.org/10.1186/s13613-025-01470-y
Van Duffel, L., et al. (2022). Accuracy of C-reactive protein and procalcitonin for bacterial infections in persistent fever. Open Forum Infectious Diseases, 9(9), ofac434. https://doi.org/10.1093/ofid/ofac434
Wang, S., et al. (2019). Serum procalcitonin and C-reactive protein to differentiate potential bacterial infection. Journal of Clinical Neuroscience, 68, 235–239. https://doi.org/10.1016/j.jocn.2019.07.046
Zhao, Z., et al. (2018). Role of C-reactive protein and procalcitonin in distinguishing infectious fever from tumor fever in lung cancer patients. Medicine, 97(33), e11871. https://doi.org/10.1097/MD.0000000000011871
Descargas
Publicado
Número
Sección
Licencia
Derechos de autor 2025 José Alberto Trejo Santiago, Ana Paula Calderón Aguirre, Jorge Angel Velasco Espinal, Ingrid Monserrat Jaimes Hernández, José Uriel Cornejo Quezada, Alexa Fernanda Uriostegui Navarro, Javier Gerardo Pérez Aparicio (Autor/a)
Esta obra está bajo una licencia internacional Creative Commons Atribución 4.0.
Los artículos publicados en la revista se distribuyen bajo la licencia Creative Commons Atribución 4.0 Internacional (CC BY 4.0). Esta licencia permite a terceros descargar, copiar, distribuir, adaptar y reutilizar una obra, incluso con fines comerciales, siempre que se otorgue el crédito adecuado al autor original.
